Japan Medical Dynamic Marketing, Inc. · TSE:7600

Japan Medical Dynamic Marketing — H1 FY2025 Earnings Presentation

26 slides from Japan Medical Dynamic Marketing's earnings presentation, Nov 12, 2024

  1. Slide 1: Financial Results Briefing for the Six Months Ended, FYE March 2025

    Japan Medical Dynamic Marketing,INC. The Six Months Ended of Financial Results Briefing for the Fiscal Year Ending March 2025 November 12, 2024 Representative Director and President Toshiyuki Hironaka TSE Prime Market Securities code：7600 Copyright © Japan Medical Dynamic Marketing, INC. All Rights

  2. Slide 2: Agenda

    - Agenda - Results for the Six Months Ended of -Agenda- 1 ． ２ ． Forecast for the FYE March 2025 P.19 P. 3 FYE March 2025 - Key Assumptions P.20 - Consolidated net sales P. 4 - Consolidated Income Statement P.21 - Consolidated Statement of Income P. 5 Comparative YoY Analysis of Operating - Consolida

  3. Slide 3: Results for the Six Months Ended FYE March 2025

    Results for the Six Months Ended of FYE March 2025 TSE Prime Market Securities code：7600 3

  4. Slide 4: Consolidated Net Sales

    FYE Mar. 2025 Six Month Ended Results Consolidated Net Sales Sales 11,817M yen Recorded the highest YoY Change （vs23/9＋7.9%） consolidated sales in the （Unit : Millions of yen） interim period 14,000 12,000 11,817M yen 10,000 Japanese Market 【After sales deductions】 8,000 6,341M yen （vs23/9 ＋3.5％） 6,0

  5. Slide 5: Consolidated Income Statement

    FYE Mar. 2025 Six Month Ended Results Consolidated Income Statement FYE Mar.2025 FYE Mar.2024 YoY change interim period interim period （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results Results sales change change sales Net sales 11,817 100.0 +865 +7.9 10,952 100.0 Cost of sal

  6. Slide 6: Prior Year Operating Profit Comparison Analysis

    FYE Mar. 2025 Six Month Ended Results Prior Year Operating Profit Comparison Analysis Operating Operating income was up 50M yen YoY due to higher gross profit (+360M yen) on higher sales, Profit which offset the impact of yen depreciation (-160M yen) and higher SG&A expenses 669M¥ (-150M yen) relate

  7. Slide 7: Consolidated Sales by Major Products

    FYE Mar. 2025 Six Month Ended Results Consolidated Sales by Major Products FYE Mar.2025 FYE Mar.2024 YoY change interim period interim period （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Results change change Results sales sales Japan 6,341 53.7 +212 +3.5 6,129 56.0 Joint 2,373

  8. Slide 8: Japanese Market

    Japanese Market 8

  9. Slide 9: Total Sales in Japan

    Japanese Market Total Sales in Japan Sales 6,341M yen Review YoY Change （vs23/9＋3.5%）  Recorded the highest sales in the interim period （Unit : Millions of yen） The number of cases acquired increased in all 7,000 product categories, increasing by 212 million yen (+3.5%) compared to the same period

  10. Slide 10: Sales in Japan – Joint Replacement

    Japanese Market Sales in Japan – Joint Replacement Sales 2,373M yen Review YoY Change （vs23/9＋0.5%） *1 BHA：Bipolar Hip Arthroplasty 【Artificial Hip Joints】 （Unit : Millions of yen）  Year-on-year growth. 3,000 The number of cases of new product ODEV Products “Promontory Hip Stem” has increased. Thir

  11. Slide 11: New product information: Ovation Tribute NEO Stem

    【New product information】 Ovation Tribute NEO Stem In the Japanese market, a new product with a new concept has been added to our artificial hip joint product group, and we are expecting to expand domestic sales. Artificial hip joints stem “Ovation Tribute NEO Stem” 【Features of the new product】 （Sa

  12. Slide 12: Sales in Japan – Trauma

    Japanese Market Sales in Japan – Trauma Sales 2,134M yen Review YoY Change （vs23/9＋3.6%）  Femoral neck fracture treatment products （Unit : Millions of yen） PHS：Continued double-digit growth. 3,000 ODEV Products  ASULOCK(Third-party product)： Third-party Products Due to increased competition, a dec

  13. Slide 13: Sales in Japan – Spine

    Japanese Market Sales in Japan – Spine Sales 1,749百万円 Review YoY Change （vs23/9＋6.9％）  BKP：KMC Balloon Kyphoplasty (Third-party Products) （Unit : Millions of yen） Double-digit growth as the market expands 2,000  Cervical Plate ODEV Products Lince Plate, Third-party Products New Products “Linceα Pl

  14. Slide 14: U.S. Market

    U.S. Market 14

  15. Slide 15: Total U.S. Sales

    U.S Market Total U.S. Sales Sales ＄35.9M Review YoY Change （vs23/9＋5.3%）  Recorded the highest sales in the （Unit ： Million of dollars） interim period 40 （vs23/9 ＋$1,815K US） 35  Interim sales increased due to the growth of the new customer base acquired last 30 year and this year, and the number

  16. Slide 16: U.S. Sales – Knee Joint Replacement

    U.S Market U.S. Sales – Knee Joint Replacement Sales ＄24.5M Review YoY Change （vs23/9＋8.4%）  BKS TriMax：Double-digit growth （Unit ： Million of dollars） BKS Revision Knee：Continued growth In addition to recruiting new clients, an increase in the 30 number of cases among existing clients contributed

  17. Slide 17: U.S. Sales – Hip Joint Replacement

    U.S Market U.S. Sales – Hip Joint Replacement Sales ＄11.2M Review YoY Change （vs23/9▲0.5%）  Alpine Hip Stem：Continued growth. （Unit ： Million of dollars）  Entrada Hip Stem , Ovation Tribute Stem： 15 Decrease in number of cases. Main Products Decrease in Double- number of cases digit growth 10 Entr

  18. Slide 18: New product information: Trivicta Hip Stem

    【New product information】 Trivicta Hip Stem We aim to acquire new customers by introducing new products with a triple taper stem, which is in increasing demand in the U.S. market. Artificial hip joints stem “Trivicta Hip Stem” 【Features of the new product】 （Sales will begin in from Sep. 2024）  The

  19. Slide 19: Forecast for the FYE March 2025

    Forecast for the FYE March 2025 TSE Prime Market Securities code：7600 19

  20. Slide 20: Key Assumptions

    FYE Mar. 2025 Forecasts Key Assumptions Assumptions for the Forecast of Full-Year for the FYE 2025 Exchange Rate Reimbursement Price Exchange Rate（US＄） Fluctuation Impact Reductions Reimbursement price reductions For every ¥/US$ weakening, Assumed exchange rate of approx. 0.3%. the Impact on Operati

  21. Slide 21: FYE Mar. 2025 Forecasts Consolidated Income Statement

    FYE Mar. 2025 Forecasts Consolidated Income Statement FY2025 YoY change FY2024 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast Results sales change change sales Net sales 25,200 100.0 +2,022 +8.7 23,177 100.0 Cost of sales 9,150 36.3 +734 +8.7 8,415 36.3 SG&A 14,200 56.3 +

  22. Slide 22: Forecast Consolidated Sales by Major Products

    FYE Mar. 2025 Forecasts Consolidated Sales by Major Products FY2025 YoY change FY2024 （Unit : Millions of yen , ％） Ratio to Amount of Ratio of Ratio to Forecast sales change change Results sales Japan 13,500 53.6 +495 +3.8 13,004 56.1 Joint 5,060 20.1 +127 +2.6 4,932 21.3 Trauma 4,670 18.5 +106 +2.3

  23. Slide 23: Main initiatives for the FYE March 2025

    2025年3月期 通期業績予想 Main initiatives for the FYE March 2025 (53rd fiscal year) Area Details of Initiatives  Product Portfolio Review. Development  Accelerate new product development to expand product lineup. SAICO PROJECT  Reduction of manufacturing costs by strengthening in-house P.24 manufacturing

  24. Slide 24: SAICO PROJECT

    SAICO PROJECT Abbreviation for Strategic Actionable Initiatives for Cost Optimization. The project launched with the aim of reducing costs by strengthening the Group's in- What is SAICO PROJECT? house manufacturing capacity and reducing costs by strengthening procurement capabilities, It was launche

  25. Slide 25: SAICO PROJECT – Procurement capabilities

    SAICO PROJECT 2-2. Cost reduction and risk reduction by 2-3. Cost reduction and risk reduction by strengthening procurement capabilities. strengthening procurement capabilities. Supplying medical instruments manufactured in Reducing manufacturing costs by procuring in yen China to the U.S. Medical i

  26. Slide 26: Contributing to Medical Care Through Advanced Medical Devices

    Contributing to Medical Care Through the Development and Sale of Advanced Medical Devices. Japan Medical Dynamic Marketing,INC. E-MAIL WEB SITE Investor Relations Office ir@jmdm.co.jp https://www.jmdm.co.jp/en/ Regarding forward-looking statements  Statements regarding the future, such as business

Japan Medical Dynamic Marketing — H1 FY2025 Earnings Presentation on 6ix